BioSpace News Archive

Akili Interactive today announced that management will present at Chardan’s Prescription Digital Therapeutics Half-Day Summit on Monday, April 11, 2022 at 2:00 p.m. E.T.

ADC Therapeutics SA announced today that a permanent J-code, J9359, has been issued for ZYNLONTA® by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2022.

Independent specialty pharmacy DirectRx announced today the launch and implementation of DirectFlow technology, designed to streamline the process of communicating patient information between physicians’ offices and the DirectRx pharmacy team.

Meridian Michigan announced today that it has appointed Dr. Kay Judge as its new Chief Medical Officer, effective April 10 , 2022.

Poolbeg Pharma announces that at the Annual General Meeting held at 11:00am today, all resolutions were duly passed with in excess of 99.9% approval.

Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, will present new findings from its fragmentomics-based platform at the American Association for Cancer Research 2022 Annual Meeting.

Ardelyx, Inc., a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, announced the launch of IBSRELA, the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation in adults.

Harmony Biosciences Holdings, Inc. announced that Harmony’s President and CEO, John C. Jacobs, will present a company update and host investor meetings at the upcoming 21st Annual Needham Virtual Healthcare Conference.

Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin its Revitalize-2 pivotal study.

Astria Therapeutics, Inc. granted equity awards on April 1, 2022 under Astria’s 2022 Inducement Stock Incentive Plan.